echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Blood testing in 2022 will provide a breakthrough in Alzheimer's disease and Parkinson's disease research

    Blood testing in 2022 will provide a breakthrough in Alzheimer's disease and Parkinson's disease research

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     

    In the past few decades, despite advances in biomedicine in cancer and other diseases, neuroscience has proven to be a difficult problem
    .

    However, with the advent of new detection methods for Parkinson's and Alzheimer's, this situation may soon change
    .

    We are expected to make some exciting progress in 2022, including new methods to detect the accumulation of certain proteins in the brain, and broader and more convenient blood screening methods
    .



    The recognition rate of Oxford Parkinson's disease screening is as high as 89%

    This month, researchers at the Oxford Parkinson’s Disease Centre demonstrated the rationale for a possible new disease test
    .

    A sample of cerebrospinal fluid is collected from the lower part of the spine through a lumbar puncture
    .
    Researchers use a method called real-time shock-induced conversion to obtain samples

    .

    Mix the specially labeled α-synuclein particle samples to observe and analyze the protein reaction, including whether the characteristic protein clumps begin to grow
    .

     

    This detection method is based on previous studies on α-synuclein, and has been proven to accurately and repeatedly identify 89% of Parkinson's patients, while excluding 96% of non-Parkinson's patients
    .

    However, since no link between diagnosis and symptom severity has been found, further research is needed to link the test to the measurement of Parkinson's disease progression, but the test method has been shown to provide a window to understand the molecular mechanisms of the brain
    .

    It is worth noting that α-synuclein is the core of Parkinson's disease research, such as ACI Immuno Biotechnology, which is also using this protein as a PET imaging tracer and a target for antibody therapy and vaccine development
    .

     


    A drop of blood detects Alzheimer's disease

     

    C2N Diagnostics, which develops blood tests for Alzheimer's disease, will introduce a new test method from the end of 2020
    .
    The test can detect early signs of a patient's memory loss

    .

    The test relies on mass spectrometry to measure the floating of amyloid beta peptide and different versions of apolipoprotein E in the blood
    .
    These proteins are common risk factors for Alzheimer's disease

    .

    Although this test alone cannot diagnose Alzheimer's disease, this non-invasive diagnostic method can be used for a wider range of clinical evaluations
    .

    C2N said that the Precivity AD test can help predict the state of amyloid plaques in the brain, which is also one of the hallmarks of neurodegenerative diseases
    .

    Recent data even show that the accuracy of the test is basically the same as that of the PET scan
    .

    In addition, as the Aduhelm therapy targeting amyloid is approved by the FDA this year, there may be a high demand for detection tools for objective measurement of disease biomarkers in the future
    .

    Quanterix, another testing and research company, said that the detection of specific types of tau in blood samples may better explain the development of this disease than amyloid
    .

    The technology produced by the company has been used in Biogen
    .
    There are also clinical trials by Eli Lilly

    .

    The researchers found that the Simoa blood test can look for the presence of a tau protein called pau-181 in the blood of patients
    .
    Identify rare neurodegenerative diseases (called frontotemporal degeneration)

    .

    Although the test is currently only used for research, Quanterix's blood test received a breakthrough certification from the FDA in October last year
    .

    The company will continue to develop its potential as a clinical diagnostic aid for Alzheimer's disease, including for people over 50
    .

    Patients who show signs of early cognitive decline need to be tested
    .



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.